Hemostemix Receives FDA Support for Its Basket Protocol Approach
Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem...
Clinical Trial
From Awareness to Action: Linus Health Drives the Next Era of Early Brain Health Detection
Expanding adoption, evidence, and innovation to support earlier identification and intervention across care and researchBOSTON, Jan. 16, 2026 /PRNewswire/ --...
AllyGPO and BioCareSD Welcome Retina Associates of Cleveland, Highlighting the Market Need for New Transparent, Technology-Forward Options
FRISCO, Texas and TEMPE, Ariz., Jan. 16, 2026 /PRNewswire/ -- AllyGPO® and BioCareSD®, a strategic partnership serving community-based specialty practices,...
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE...
CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results
GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC)...
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 15,...
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of kidney transplant...
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
The Science, Clinical Promise, & Market OutlookMELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc”...
Metabolon Appoints Celia Reyes as Vice President of Human Resources
Celia Reyes will lead Metabolon's global people strategy as the company continues to scale in the evolving multiomics marketplaceMORRISVILLE, N.C.,...
Metabolon Appoints Celia Reyes as Vice President of Human Resources
Celia Reyes will lead Metabolon's global people strategy as the company continues to scale in the evolving multiomics marketplaceMORRISVILLE, N.C.,...
Aspire Biopharma Announces Reverse Stock Split
ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a...
Zomedica Announces “Fourth Friday at Four” Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth
January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy ANN ARBOR, MI / ACCESS Newswire / January...
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program ProgressMOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx,...
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
Sarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) today announced that it will...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression...
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide...
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement...